Stocks Health care GALT
NASDAQ · Health careGalectin Therapeutics Inc (GALT)
It posted a net loss of $27.8M. At June 30, 2026 it held $13.3M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.
What Galectin Therapeutics Inc does
Galectin Therapeutics Inc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker GALT.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$30.8M | -$0.48 | n/a |
| 2024 | n/a | -$47M | -$0.76 | n/a |
| 2023 | n/a | -$41.1M | -$0.74 | n/a |
| 2022 | n/a | -$38.8M | -$0.65 | n/a |
| 2021 | n/a | -$30.5M | -$0.52 | n/a |
| 2020 | n/a | -$23.5M | -$0.41 | n/a |
Latest SEC filings
What Galectin Therapeutics Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 14, 2026
- August 14, 2026Quarterly report 10-Q · period to June 30, 2026
- August 4, 2026Activist stake changed SCHEDULE 13D/A
- August 4, 2026
- June 23, 2026
- May 15, 2026
- May 15, 2026Quarterly report 10-Q · period to March 31, 2026
- March 31, 2026
- March 31, 2026
- March 31, 2026Annual report 10-K · period to December 31, 2025
Questions about GALT
What does Galectin Therapeutics Inc do?
Galectin Therapeutics Inc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker GALT.
Is Galectin Therapeutics Inc profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $27.8M.
When did Galectin Therapeutics Inc last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026.
Similar companies
Follow GALT
Get an email when Galectin Therapeutics Inc files with the SEC: results, executive changes, material agreements and annual reports.
Follow GALT: get an email when it filesWhere the numbers come from
Financial figures are the values Galectin Therapeutics Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.